Chugai Pharmaceutical Co Ltd (4519.T)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|70||2018||Chairman of the Board, Representative Director|
|65||2018||President, Chief Executive Officer, Representative Director|
|60||2012||Vice Chairman of the Board, Representative Director|
|2017||Chief Financial Officer, Senior Executive Officer, Director of Finance & Accounting, Senior Manager of IT, Senior Manager of Finance|
|2017||Senior Executive Officer, Director of Legal Affairs|
- BRIEF-Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan
- BRIEF-Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit
- Nikkei rallies as markets hope China and U.S. will avoid full-blown trade war
- UPDATE 2-Pfizer's biosimilar of Roche's Rituxan succeeds in study
- Swiss stocks - Factors to watch on Jan 19